A Non-interventional Study Evaluating the Clinical Benefit and Effectiveness of Quetiapine Fumarate Extended

NCT00922090 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1494

Last updated 2010-03-12

No results posted yet for this study

Summary

The primary objective of this NIS is to assess the clinical benefit subjects derive from taking seroquel XR, using the CGI-CB. The secondary objective is to assess the effectiveness,safety and tolerability of seroquel XR tablets.

Conditions

Sponsors & Collaborators

Principal Investigators

  • JoonWoo Bahn, MD, PhD · AstraZeneca Korea

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00922090 on ClinicalTrials.gov